<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prototypic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene, the <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> gene (RB/ p105), is mutated in a variety of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, to date, mutational data on <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> family members p107 and RB2/p130 in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> is lacking </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the expression of pRb2/p130 by immunocytochemistry and Western blot analysis in a panel of human <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> and lymphoid cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>Only the lymphoid cell lines showed an abnormal cytoplasmic localization of pRb2/p130, suggesting possible alterations within the region of nuclear localization signaling </plain></SENT>
<SENT sid="4" pm="."><plain>We screened these cell lines for genetic alterations of the RB2/p130 gene in the region of the putative bipartite nuclear localization signal (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLS</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>This region is highly homologous with that of the RB/p105 gene </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, we screened four primary Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> for genetic alterations in the RB2/p130 gene </plain></SENT>
<SENT sid="7" pm="."><plain>Naturally occurring mutations, which disrupt the putative bipartite <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLS</z:e>, were found in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines and <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, but not in the <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> cell lines, where <z:mpath ids='MPATH_458'>normal</z:mpath> nuclear localization of the protein was detectable </plain></SENT>
<SENT sid="8" pm="."><plain>Site-directed mutagenesis and transfection assay using <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLS</z:e> mutants displayed markedly reduced biological activity as measured by flow cytometric analysis </plain></SENT>
<SENT sid="9" pm="."><plain>This study clearly describes RB2/ p130 as an important target for mutations and subsequent inactivation in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> pathogenesis, thus validating that RB2/p130 is a classical <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene </plain></SENT>
</text></document>